Targeted protein degraders of SARS-CoV-2 Mpro are more active than enzymatic inhibition alone with activity against nirmatrelvir resistant virus

Author(s):

Baolong Pan, Simon J. Mountford, Maki Kiso, Danielle E. Anderson, Georgina Papadakis, Kate E. Jarman, Danielle R. Tilmanis, Belinda Maher, Thomas Tran, Jake Shortt, Seiya Yamayoshi, Yoshihiro Kawaoka, Philip E. Thompson, Sam A. Greenall, Nadia Warner

Details:

Communications Medicine, Volume 5, Issue 1, 2025-12-01, Article number 140

Article Link: Click here

Affiliations:

• The Peter Doherty Institute for Infection and Immunity
• The Institute of Medical Science, The University of Tokyo
• Monash University
• Walter and Eliza Hall Institute of Medical Research
• University of Melbourne
• The University of Tokyo
• University of Wisconsin School of Veterinary Medicine
• National Center for Global Health and Medicine
• Massachusetts Institute of Technology
• Monash Health